Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAVE-EPA: Icosapent Ethyl in Preclinical Alzheimer's Disease
NCT02719327Phase 3Completed
- Sponsor
- VA Office of Research & Development
- Start
- Jun 2017
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of omega-3-acid triglycerides in Alzheimer's disease (AD), sponsored by VA Office of Research & Development. Started Jun 2017; status: completed.
02
Drugs
omega-3-acid triglycerides
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02719327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02719327.